C

Crescent Biopharma

Clinical-stage biotech developing solid-tumor therapies

Senior Manager - Corporate Communications & Investor Relations

PR & CommunicationsConfirmed live in the last 24 hours
Full-timeWaltham, MA, USAIn-person

About the Job

Requirements

  • A bachelor's degree in communications, public relations, journalism, business, finance, life sciences, or a related field.
  • Five to seven years of relevant experience in corporate communications, internal communications, investor relations, public relations, or a related function.
  • Experience developing clear, high-quality communications for employees, executives, investors, analysts, media, and other external stakeholders.
  • Working knowledge of public-company communications and investor relations deliverables, including earnings materials, corporate presentations, press releases, key messages, and Q&A documents.
  • Exceptional writing, editing, and presentation-development skills, with the ability to translate scientific, clinical, and business information into concise, audience-appropriate content.
  • Demonstrated project-management and operational skills, including the ability to coordinate executive content, company meetings, external events, vendors, timelines, and multiple stakeholders.
  • Strong judgment, discretion, attention to detail, and commitment to accuracy in a fast-paced, high-visibility environment.
  • A collaborative and proactive working style, with the ability to influence across functions and organizational levels while managing competing priorities.

Responsibilities

  • Help lead the company's internal communications strategy, connecting employees to its mission, vision, strategy, and culture, in partnership with the Human Resources team.
  • Own communications and end-to-end coordination for all-company meetings and various events, including developing presentation content and managing logistics; support community engagement and volunteerism opportunities.
  • Draft internal communications materials for company announcements, executive messages, and the company intranet.
  • Support execution of integrated communications campaigns across company channels and identify opportunities to extend stories across internal and external audiences.
  • Support the company's corporate social media presence, including editorial planning, content development, and content calendars that highlight the pipeline, people, culture, and patient-focused mission.
  • Assist with management of the corporate website and other digital communications channels, ensuring content is accurate, current, and aligned with corporate messaging.
  • Support development of external communications, including corporate presentations, press releases, key messages, and Q&A materials.
  • Coordinate logistics and prepare briefing materials for investor and analyst meetings, conference participation, and other external engagements.
  • Coordinate investor inquiries and maintain investor-relations contact databases, investor-targeting lists, and analytics.
  • Conduct competitive intelligence across the peer group and maintain regular monitoring reports.
  • Monitor sell-side research notes, media coverage, industry and peer-company news, and social media activity; prepare regular summaries, reporting, and insights.
  • Perform other communications and investor-relations responsibilities as business needs evolve.

Desired Qualifications

  • Biotechnology or pharmaceutical industry experience is strongly preferred.
  • Familiarity with corporate websites, social media platforms, content calendars, media monitoring, and investor relationship management tools.

About the Company

Crescent Biopharma

Clinical-stage biotech developing solid-tumor therapies

Crescent Biopharma develops oncology therapies for solid tumors, led by CR-001, a tetravalent bispecific antibody that blocks PD-1 and VEGF to boost anti-tumor immunity while inhibiting tumor blood vessel growth. CR-001 sits in a global Phase 1/2 ASCEND trial, and the pipeline also includes CR-002, an anti-PD-L1 antibody-drug conjugate, and CR-003, an ITGB6-targeted ADC. The company differentiates itself by combining immune checkpoint blockade with VEGF inhibition and other targeted modalities to build an immuno-oncology backbone for solid tumors, supported by strategic partnerships and substantial private placements. Crescent’s goal is to advance multi-agent regimens toward regulatory approval and commercial development for patients with solid tumors.

Company size
51-200
Company stage
IPO
Headquarters
Waltham, MA
Founded
2003

Recently Posted Jobs

Explore more opportunities at Crescent Biopharma

See more jobs